Aerosolized Randomized Iloprost Study II (AIR - II) Long-Term Safety, Tolerability, and Clinical Effects of Iloprost Inhalation in Patients With Primary or Secondary Pulmonary Hypertension
NCT00414687 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 63
Last updated 2009-05-15
Summary
The purpose of this study is to determine whether the study drug is effective in the long-term treatment of primary or secondary pulmonary hypertension
Conditions
- Hypertension, Pulmonary
Interventions
- DRUG
-
Ventavis (Iloprost, BAYQ6256)
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Bayer Study Director · Bayer
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 70 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 1998-07-31
- Completion
- 2001-05-31
More Related Trials
-
Post-Marketing Surveillance of Ventavis® in Chinese Patients With Primary Pulmonary Hypertension (PPH)
NCT00882947 ·Status: COMPLETED
-
Non-interventional Study on Compliance of Inhaled Treatment With Ventavis in Patient With Pulmonary Hypertension
NCT01971450 ·Status: COMPLETED
-
Observation of Patients With Primary Pulmonary Hypertension Receiving Prescribed Ventavis Inhalation Therapy Regarding Safety and Efficacy for up to 4 Years
NCT00250640 ·Status: COMPLETED
-
Efficacy of Ventavis Used in Real-life Setting.
NCT01355380 ·Status: COMPLETED
-
Effects of Ventavis in Patients With Pulmonary Hypertension (PH) Secondary to Chronic Obstructive Pulmonary Disease (COPD)
NCT01437878 ·Status: TERMINATED ·Phase: PHASE2
-
Inhaled Iloprost in Adults With Abnormal Pulmonary Pressure and Associated With Idiopathic Pulmonary Fibrosis
NCT00109681 ·Status: COMPLETED ·Phase: PHASE2
-
Effect of BMPR-2 Gene Mutations on Hemodynamic Response by Iloprost Inhalation in Pulmonary Arterial Hypertension
NCT01054105 ·Status: COMPLETED
-
Trial of Iloprost Inhaled Solution as Add-On Therapy With Bosentan in Subjects With Pulmonary Arterial Hypertension (PAH)
NCT00086463 ·Status: COMPLETED ·Phase: PHASE2
-
Iloprost Power 15 in Pulmonary Arterial Hypertension
NCT00709956 ·Status: COMPLETED ·Phase: PHASE3
-
Observational Description of Compliance for the Daily Ventavis Use Via the Insight Program in Class III Pulmonary Arterial Hypertension Patients
NCT01781052 ·Status: COMPLETED
-
Safety and Efficacy of Inhaled Iloprost in Pediatric Patients With Pulmonary Arterial Hypertension
NCT00453414 ·Status: WITHDRAWN ·Phase: PHASE2
-
Non-interventional, Postauthorization Safety Study of Ventavis for Pulmonary Arterial Hypertension (PAH)
NCT02825160 ·Status: COMPLETED
-
Transitioning To IV Remodulin From Ventavis in Patients With PAH: Safety, Efficacy and Treatment Satisfaction
NCT00458042 ·Status: TERMINATED ·Phase: PHASE4
-
Examination of Ventavis (Iloprost) Inhalation Behavior Using the I-Neb AAD System in Patients With Pulmonary Arterial Hypertension When Switching the Iloprost Nebulizer Solution for Inhalation From 10 μg/mL (V10) to 20 μg/mL (V20)
NCT02826252 ·Status: COMPLETED
-
The "Power 15 Study": Safety Study of Inhalation of Ventavis With the Power Disc-15 Setting
NCT00467896 ·Status: TERMINATED ·Phase: PHASE2
-
Hypertension Study of Ventavis® Inhalation Therapy in the Treatment of Patients With Pulmonary Arterial Hypertension (VENIS)
NCT01062282 ·Status: COMPLETED
-
Safety, Tolerability, and PK Parameters of Sodium Nitrite Inhalation Solution in Healthy Subjects
NCT01409122 ·Status: COMPLETED ·Phase: PHASE1
-
Iloprost-Study: Comparison of Nitric Oxide to Iloprost (Ventavis) for Treatment of Pulmonary Hypertension in Children After Cardiopulmonary Bypass Surgery
NCT00235521 ·Status: COMPLETED ·Phase: NA
-
Safety Study Extension of Iloprost Power 15 in Pulmonary Arterial Hypertension
NCT00709098 ·Status: COMPLETED ·Phase: PHASE3
-
Clinical Study of Pulsed, Inhaled Nitric Oxide Versus Placebo in Symptomatic Subjects With PAH
NCT02725372 ·Status: TERMINATED ·Phase: PHASE3
-
Ventavis® Registry Protocol
NCT00902603 ·Status: TERMINATED
-
Effects of Iloprost on Hypoxic Pulmonary Vasoconstriction and Exercise Capacity at High Altitude
NCT00708565 ·Status: UNKNOWN ·Phase: PHASE1
-
Inhaled Aerosolized Prostacyclin for Pulmonary Hypertension Requiring Inhaled Nitric Oxide
NCT02170519 ·Status: TERMINATED ·Phase: PHASE4
-
Comparative PK PD Study in PAH Patients (Fox vs. I-Neb)
NCT02032836 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
The "VISION" Trial: Ventavis Inhalation With Sildenafil to Improve and Optimize Pulmonary Arterial Hypertension
NCT00302211 ·Status: TERMINATED ·Phase: PHASE3